The agency accepted its New Drug Application for AXS-12, a treatment for cataplexy in narcolepsy, with a decision deadline set for May 2027. Even better? No advisory committee meeting is planned; a signal the FDA sees this as a straightforward case. This is more than just another drug filing. It’s a step toward proving Axsome can turn its CNS pipeline into real revenue. Right now, the company is still burning cash, relying on Auvelity and Sunosi to keep the lights on. But AXS-12 could be the next leg in that journey; targeting a rare, high-need condition with limited competition. Analysts project Axsome could hit $2.5 billion in revenue by 2029. Some bullish forecasts even see $3.8 billion. But here’s the catch: none of that matters unless Axsome nails commercial execution; pricing, insurance coverage, physician adoption. The FDA nod is a green light. The market will decide if it’s a green signal. For now, the stock may be undervalued; Simply Wall St’s fair value sits at $282.51, suggesting 17% upside. But this isn’t a “buy and forget” play. It’s a story unfolding; with risk, reward, and runway. If you’re watching biotech, Axsome is quietly assembling the pieces.